Clinical Trial Update: A Study of Intermittent Doses of CERC-301 in MDD [Phase 2]

View source ↗

Summary

Phase 2 trial updating intermittent dosing of CERC-301 in major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CERC-301

Snippet

Sponsor: Avalo Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED